Abnormal serum lipid levels (dyslipidemias) are important risk factors for cardiovascular and other atherosclerotic diseases. Drugs that normalize lipid abnormalities are recognized as essential in the treatment of these diseases. However, many lipid disorders are complex, resistant to simple treatment strategies. While diet certainly contributes to the development of dyslipidemias, there are also important genetic factors at play. Since lipid disorders are under complex genetic and physiological regulation, a thorough understanding of these mechanisms is essential for developing improved therapies. Thus, researchers study animal models that share genetic and physiological traits with human but can also be manipulated genetically. The mouse model system is commonly used to understand lipoprotein metabolism, yet mice lack an enzyme critical for cholesterol transfer between lipoprotein classes (cholesterol ester transfer protein, CETP).
acids into the circulation is dependent on lipoprotein production. Additionally, they examine the metabolic fate of exogenously delivered fatty acids by assaying their incorporation into complex lipids. Finally, they demonstrate that using this technique, they can detect lipid/lipoprotein abnormalities caused by a genetic mutation (microsomal triglyceride transfer protein) and an inhibitor of a lipid-metabolizing enzyme (acylCoA:cholesterol acyltransferase).
Implications and future directions:
The authors' results suggest that zebrafish yolk lipid transport and metabolism is a tractable model to study lipid and lipoprotein biology, regulation, and metabolism.
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